XRP Price Today at $2.49, down 2.59%. Ripple consolidates as Noomez ($NNZ) presale gains early traction with burns, audits, and a 28-stage deflationary model.XRP Price Today at $2.49, down 2.59%. Ripple consolidates as Noomez ($NNZ) presale gains early traction with burns, audits, and a 28-stage deflationary model.

XRP Price Today: Ripple Struggles at $2.49 as Noomez ($NNZ) Presale Gains Momentum

Noomez

XRP price today stands at $2.49, down 2.59% in the last 24 hours, with trading volume slipping below $5.4 billion.

The token’s market cap remains near $150 billion, but its momentum has cooled as traders reassess short-term catalysts.

While Ripple continues to consolidate near key resistance zones, a new presale coin; Noomez ($NNZ) is capturing increasing investor attention after raising more than $4,514.81 in just two days.

XRP Price Prediction 2025

chart42727

Ripple’s 2025 forecast suggests moderate upside potential, driven by gradual institutional adoption and ongoing integration in cross-border settlements. Analysts project steady growth throughout 2025, with XRP trading between $2.43 and $2.83, averaging $2.58 by December; a 12.9% annual gain.

Key takeaways for 2025:

  • Institutional integration: RippleNet’s partnerships continue to grow, particularly in Asia and the Middle East.
  • Regulatory clarity: Partial legal resolution and licensing in several jurisdictions may boost confidence.
  • Utility-driven recovery: XRP’s use in payments and liquidity management remains a long-term stabilizing force.

While the forecast is optimistic, traders remain cautious about volume fatigue and selloffs near $2.80, a critical resistance zone.

XRP Price Prediction 2026–2027

Forecast models for 2026 and 2027 suggest stronger growth periods, especially as global crypto markets recover from the 2024–2025 tightening cycle. XRP is expected to move between $2.60 and $3.90 in 2026, with an average target of $3.22, reflecting potential returns above 45% from current levels.

By 2027, projections strengthen further:

  • Min Price: $2.79
  • Avg Price: $3.61
  • Max Price: $4.06
  • Growth Potential: +61.78%

Analysts see a possible reacceleration toward $5 if Ripple expands its remittance corridor partnerships or integrates with central bank digital currency (CBDC) initiatives.

However, XRP still lacks strong speculative momentum compared to meme assets like Dogwifhat (WIF) or emerging presales like Noomez ($NNZ), which are currently capturing retail liquidity.

Noomez ($NNZ): A Structured Presale Built on Story and Precision

Noomez 3 1

Noomez ($NNZ) is a deflationary meme coin with a fixed 280 billion supply, running a 28-stage presale priced from $0.0001 to $0.028.

Unsold tokens are burned each stage, and one verified wallet wins a Stage X Million Airdrop per round. Stage 1 has already raised $4,572 from 30 holders, backed by a full audit, 15% liquidity lock and team vesting (6–12 months).

Its roadmap is divided into five arcs blending lore, utility, and on-chain milestones:

  • Arc I – The Foundation (Q3 2025): Channels open, whitelist, dashboard, and audit.
  • Arc II – The Awakening (Q4 2025): 28-stage presale, “Sell Out or 7 Days Max,” airdrops, live Gauge.
  • Arc III – The Vault Signal (Q1 2026): Stage 14 USDT rewards + burns.
  • Arc IV – The Lunar Ascension (Q2 2026): Stage 28 28M NNZ, NFTs, partner rewards.
  • Arc V – The Engine Ignites (Q3 2026): DEX listing, staking, Access Engine token drops.

The Bottom Line

While XRP remains one of crypto’s most established assets, its current stagnation near $2.49 has prompted traders to explore alternative high-upside opportunities. Noomez represents one of those rare early-stage presales combining gamified design, verified audits, and a deflationary supply model.

As XRP eyes a steady climb through 2026–2027, Noomez’s transparent presale and story-driven approach are already gaining momentum.

The project’s structure and fairness make it one of the most talked-about meme coin launches of 2025, and early investors can still buy Noomez during its initial stage before prices rise.

It’s a clear reminder that innovation in crypto often comes from new, creative entrants, not just legacy players.

For More Information:

Website: Visit the Official Noomez Website
Telegram: Join the Noomez Telegram Channel
Twitter: Follow Noomez ON X (Formerly Twitter)

This article is not intended as financial advice. Educational purposes only.

Market Opportunity
XRP Logo
XRP Price(XRP)
$1.4222
$1.4222$1.4222
-1.65%
USD
XRP (XRP) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26